CTKB vs. TXG, TRNS, EYPT, ALNT, LAB, AEHR, QSI, QTRX, SENS, and MASS
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Cytek Biosciences vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.
In the previous week, 10x Genomics had 8 more articles in the media than Cytek Biosciences. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Cytek Biosciences. 10x Genomics' average media sentiment score of 0.97 beat Cytek Biosciences' score of 0.59 indicating that 10x Genomics is being referred to more favorably in the media.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 10.3% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cytek Biosciences has a net margin of -5.71% compared to 10x Genomics' net margin of -25.14%. Cytek Biosciences' return on equity of -2.90% beat 10x Genomics' return on equity.
10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
10x Genomics presently has a consensus target price of $14.96, indicating a potential upside of 15.00%. Cytek Biosciences has a consensus target price of $5.60, indicating a potential upside of 48.94%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than 10x Genomics.
Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
Summary
10x Genomics beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CTKB) was last updated on 7/3/2025 by MarketBeat.com Staff
Free CTKB Stock Alerts